Literature DB >> 28447972

Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations.

Adam Z Albitar1, Wanlong Ma1, Maher Albitar2.   

Abstract

Accurate detection and identification of low frequency mutations can be problematic when assessing residual disease after therapy, screening for emerging resistance mutations during therapy, or when patients have few circulating tumor cells. Wild-type blocking PCR followed by sequencing analysis offers high sensitivity, flexibility, and simplicity as a methodology for detecting these low frequency mutations. By adding a custom designed locked nucleic acid oligonucleotide to a new or previously established conventional PCR based sequencing assay, sensitivities of approximately 1 mutant allele in a background of 1,000 WT alleles can be achieved (1:1,000). Sequencing artifacts associated with deamination events commonly found in formalin fixed paraffin embedded tissues can be partially remedied by the use of uracil DNA glycosylase during extraction steps. The optimized protocol here is specific for detecting MYD88 mutation, but can serve as a template to design any WTB-PCR assay. Advantages of the WTB-PCR assay over other commonly utilized assays for the detection of low frequency mutations including allele specific PCR and real-time quantitative PCR include fewer occurrences of false positives, greater flexibility and ease of implementation, and the ability to detect both known and unknown mutations.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28447972      PMCID: PMC5564440          DOI: 10.3791/55130

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  24 in total

1.  Digital PCR.

Authors:  B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  Single nucleotide polymorphism genotyping using locked nucleic acid (LNA).

Authors:  Peter Mouritzen; Alex Toftgaard Nielsen; Henrik M Pfundheller; Yoanna Choleva; Lars Kongsbak; Søren Møller
Journal:  Expert Rev Mol Diagn       Date:  2003-01       Impact factor: 5.225

3.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

Review 4.  Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.

Authors:  Morie A Gertz
Journal:  Am J Hematol       Date:  2012-05       Impact factor: 10.047

5.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

Authors:  Marzia Varettoni; Luca Arcaini; Silvia Zibellini; Emanuela Boveri; Sara Rattotti; Roberta Riboni; Alessandro Corso; Ester Orlandi; Maurizio Bonfichi; Manuel Gotti; Cristiana Pascutto; Silvia Mangiacavalli; Giorgio Croci; Valeria Fiaccadori; Lucia Morello; Maria Luisa Guerrera; Marco Paulli; Mario Cazzola
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113

7.  Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA.

Authors:  Reid P Oldenburg; Monica S Liu; Michael S Kolodney
Journal:  J Invest Dermatol       Date:  2007-06-21       Impact factor: 8.551

8.  KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissues.

Authors:  Jérome Solassol; Jeanne Ramos; Evelyne Crapez; Majda Saifi; Alain Mangé; Evelyne Vianès; Pierre-Jean Lamy; Valérie Costes; Thierry Maudelonde
Journal:  Int J Mol Sci       Date:  2011-05-17       Impact factor: 5.923

9.  Agarose gel electrophoresis for the separation of DNA fragments.

Authors:  Pei Yun Lee; John Costumbrado; Chih-Yuan Hsu; Yong Hoon Kim
Journal:  J Vis Exp       Date:  2012-04-20       Impact factor: 1.355

10.  Biased estimates of clonal evolution and subclonal heterogeneity can arise from PCR duplicates in deep sequencing experiments.

Authors:  Erin N Smith; Kristen Jepsen; Mahdieh Khosroheidari; Laura Z Rassenti; Matteo D'Antonio; Emanuela M Ghia; Dennis A Carson; Catriona Hm Jamieson; Thomas J Kipps; Kelly A Frazer
Journal:  Genome Biol       Date:  2014-08-07       Impact factor: 13.583

View more
  1 in total

1.  FERMI: A Novel Method for Sensitive Detection of Rare Mutations in Somatic Tissue.

Authors:  L Alexander Liggett; Anchal Sharma; Subhajyoti De; James DeGregori
Journal:  G3 (Bethesda)       Date:  2019-09-04       Impact factor: 3.154

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.